What is Bio-Techne Corp's earnings per share (EPS)?

Bio-Techne Corp (TECH) reported diluted earnings per share of $0.46 for fiscal year 2025. This represents a -56.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bio-Techne Corp Financials

TECH

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE June

This page shows Bio-Techne Corp (TECH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 58/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Bio-Techne Corp has an operating margin of 8.4%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 41/100, indicating healthy but not exceptional operating efficiency. This is down from 17.8% the prior year.

Growth

Bio-Techne Corp's revenue grew 5.2% year-over-year to $1.2B, a solid pace of expansion. This earns a growth score of 42/100.

Leverage

Bio-Techne Corp carries a low D/E ratio of 0.18, meaning only $0.18 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.46, Bio-Techne Corp holds $3.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 67/100.

Cash Flow

Bio-Techne Corp converts 21.0% of revenue into free cash flow ($256.6M). This strong cash generation earns a score of 78/100.

Returns

Bio-Techne Corp generates a 3.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 20/100. This is down from 8.1% the prior year.

Altman Z-Score Safe

9.20

Bio-Techne Corp scores 9.20, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($8.3B) relative to total liabilities ($639.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Bio-Techne Corp passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

3.92x

For every $1 of reported earnings, Bio-Techne Corp generates $3.92 in operating cash flow ($287.6M OCF vs $73.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

12.0x

Bio-Techne Corp earns $12.0 in operating income for every $1 of interest expense ($102.3M vs $8.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.2B

YoY+5.2%

5Y CAGR+10.5%

10Y CAGR+10.4%

Bio-Techne Corp generated $1.2B in revenue in fiscal year 2025. This represents an increase of 5.2% from the prior year.

EBITDA

$212.2M

YoY-33.4%

5Y CAGR-2.4%

10Y CAGR+1.4%

Bio-Techne Corp's EBITDA was $212.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.4% from the prior year.

Net Income

$73.4M

YoY-56.3%

5Y CAGR-20.4%

10Y CAGR-3.8%

Bio-Techne Corp reported $73.4M in net income in fiscal year 2025. This represents a decrease of 56.3% from the prior year.

EPS (Diluted)

$0.46

YoY-56.2%

Bio-Techne Corp earned $0.46 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 56.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$256.6M

YoY+8.7%

5Y CAGR+10.8%

10Y CAGR+7.9%

Bio-Techne Corp generated $256.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 8.7% from the prior year.

Cash & Debt

$162.2M

YoY+6.8%

5Y CAGR+2.0%

10Y CAGR+11.5%

Bio-Techne Corp held $162.2M in cash against $346.0M in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.32

YoY+0.0%

Bio-Techne Corp paid $0.32 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Shares Outstanding

155M

YoY-2.1%

Bio-Techne Corp had 155M shares outstanding in fiscal year 2025. This represents a decrease of 2.1% from the prior year.

Margins & Returns

Gross Margin

64.8%

YoY-1.6pp

5Y CAGR-0.6pp

10Y CAGR-3.1pp

Bio-Techne Corp's gross margin was 64.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.6 percentage points from the prior year.

Operating Margin

8.4%

YoY-9.4pp

5Y CAGR-12.9pp

10Y CAGR-24.1pp

Bio-Techne Corp's operating margin was 8.4% in fiscal year 2025, reflecting core business profitability. This is down 9.4 percentage points from the prior year.

Net Margin

6.0%

YoY-8.5pp

5Y CAGR-25.0pp

10Y CAGR-17.8pp

Bio-Techne Corp's net profit margin was 6.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 8.5 percentage points from the prior year.

Return on Equity

3.8%

YoY-4.3pp

5Y CAGR-12.8pp

10Y CAGR-8.9pp

Bio-Techne Corp's ROE was 3.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$99.5M

YoY+2.9%

5Y CAGR+8.8%

10Y CAGR+9.3%

Bio-Techne Corp invested $99.5M in research and development in fiscal year 2025. This represents an increase of 2.9% from the prior year.

Share Buybacks

$275.7M

YoY+244.5%

5Y CAGR+40.6%

Bio-Techne Corp spent $275.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 244.5% from the prior year.

Capital Expenditures

$31.0M

YoY-50.7%

5Y CAGR-9.7%

10Y CAGR+4.5%

Bio-Techne Corp invested $31.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 50.7% from the prior year.

TECH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.2B+5.2%	$1.2B+2.0%	$1.1B+2.8%	$1.1B+18.7%	$931.0M+26.0%	$738.7M
Cost of Revenue	$429.4M+10.3%	$389.3M+6.1%	$366.9M+5.1%	$349.1M+17.1%	$298.2M+16.7%	$255.5M
Gross Profit	$790.3M+2.7%	$769.7M0.0%	$769.8M+1.8%	$756.5M+19.5%	$632.9M+31.0%	$483.2M
R&D Expenses	$99.5M+2.9%	$96.7M+4.5%	$92.5M+6.1%	$87.1M+23.4%	$70.6M+8.3%	$65.2M
SG&A Expenses	$588.5M+26.2%	$466.4M+23.3%	$378.4M+1.5%	$372.8M+14.7%	$325.0M+24.7%	$260.6M
Operating Income	$102.3M-50.5%	$206.7M-30.9%	$298.9M+0.8%	$296.6M+25.0%	$237.3M+50.7%	$157.4M
Interest Expense	$8.5M-45.9%	$15.7M+40.3%	$11.2M-0.8%	$11.3M-18.9%	$14.0M-27.3%	$19.2M
Income Tax	$25.1M+42.5%	$17.6M-67.0%	$53.2M+39.0%	$38.3M+345.7%	$8.6M-81.8%	$47.2M
Net Income	$73.4M-56.3%	$168.1M-41.1%	$285.3M+4.9%	$272.1M+93.8%	$140.4M-38.8%	$229.3M
EPS (Diluted)	$0.46-56.2%	$1.05-40.3%	$1.76+6.0%	$1.66	$0.87-85.1%	$5.82

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$295.9M+3.3%	$286.6M-9.6%	$317.0M+0.2%	$316.2M+6.4%	$297.0M+2.6%	$289.5M-5.4%	$306.1M+0.9%	$303.4M
Cost of Revenue	$104.6M+6.3%	$98.4M-16.7%	$118.2M+16.3%	$101.6M-1.5%	$103.1M-3.1%	$106.4M+3.6%	$102.8M+4.0%	$98.8M
Gross Profit	$191.3M+1.7%	$188.1M-5.4%	$198.8M-7.3%	$214.6M+10.7%	$193.9M+5.9%	$183.0M-10.0%	$203.3M-0.6%	$204.6M
R&D Expenses	$23.1M-4.6%	$24.2M-6.9%	$26.0M+5.9%	$24.6M-1.7%	$25.0M+4.8%	$23.9M-0.5%	$24.0M-6.9%	$25.8M
SG&A Expenses	$113.7M-2.2%	$116.2M-40.9%	$196.6M+30.0%	$151.3M+24.6%	$121.5M+1.9%	$119.2M-10.8%	$133.5M+19.4%	$111.8M
Operating Income	$54.5M+14.3%	$47.7M+299.7%	-$23.9M-161.6%	$38.7M-18.4%	$47.4M+18.6%	$40.0M-12.7%	$45.8M-31.6%	$67.0M
Interest Expense	$2.2M-26.0%	$2.9M+34.7%	$2.2M+8.5%	$2.0M-6.6%	$2.1M-1.3%	$2.2M-13.3%	$2.5M-37.4%	$4.0M
Income Tax	$12.8M+30.3%	$9.8M+289.3%	-$5.2M-133.0%	$15.7M+96.4%	$8.0M+21.5%	$6.6M+513.0%	$1.1M-91.1%	$12.0M
Net Income	$38.0M-0.5%	$38.2M+316.0%	-$17.7M-178.3%	$22.6M-35.3%	$34.9M+3.8%	$33.6M-17.2%	$40.6M-17.3%	$49.1M
EPS (Diluted)	$0.240.0%	$0.24	N/A	$0.14-36.4%	$0.22+4.8%	$0.21	N/A	$0.31

TECH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.6B-5.4%	$2.7B+2.5%	$2.6B+15.0%	$2.3B+1.4%	$2.3B+11.6%	$2.0B
Current Assets	$608.3M-1.5%	$617.4M-0.7%	$621.5M+2.6%	$605.6M+18.6%	$510.6M-2.0%	$520.9M
Cash & Equivalents	$162.2M+6.8%	$151.8M-15.9%	$180.6M+4.6%	$172.6M-13.3%	$199.1M+35.8%	$146.6M
Inventory	$189.4M+5.4%	$179.7M+4.7%	$171.6M+21.6%	$141.1M+20.9%	$116.7M+13.2%	$103.2M
Accounts Receivable	$206.9M-14.3%	$241.4M+10.5%	$218.5M+12.3%	$194.5M+33.8%	$145.4M+18.6%	$122.5M
Goodwill	$980.9M+0.9%	$972.7M+11.4%	$872.7M+6.2%	$822.1M-2.5%	$843.1M+15.8%	$728.3M
Total Liabilities	$639.1M+0.6%	$635.0M-5.5%	$672.2M+13.3%	$593.0M-15.3%	$700.0M+8.3%	$646.4M
Current Liabilities	$175.8M+10.3%	$159.4M+24.0%	$128.5M-27.0%	$176.0M+15.6%	$152.3M+42.8%	$106.7M
Long-Term Debt	$346.0M+8.5%	$319.0M-8.9%	$350.0M+43.8%	$243.4M-26.0%	$328.8M-4.5%	$344.2M
Total Equity	$1.9B-7.3%	$2.1B+5.2%	$2.0B+15.6%	$1.7B+8.9%	$1.6B+13.2%	$1.4B
Retained Earnings	$1.1B-19.6%	$1.3B+1.2%	$1.3B+16.6%	$1.1B+3.5%	$1.1B+2.6%	$1.1B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$2.5B-0.1%	$2.5B-1.2%	$2.6B-3.3%	$2.6B-1.0%	$2.7B-2.4%	$2.7B+1.2%	$2.7B-0.6%	$2.7B
Current Assets	$637.4M+4.6%	$609.5M+0.2%	$608.3M-3.0%	$627.2M-1.2%	$634.6M-2.1%	$648.6M+5.0%	$617.4M+1.1%	$610.6M
Cash & Equivalents	$172.9M+19.3%	$145.0M-10.6%	$162.2M+15.3%	$140.7M-20.8%	$177.5M-5.3%	$187.5M+23.6%	$151.8M+8.5%	$139.9M
Inventory	$205.4M+1.1%	$203.2M+7.3%	$189.4M-0.9%	$191.1M+1.4%	$188.4M+1.8%	$185.0M+3.0%	$179.7M+0.1%	$179.5M
Accounts Receivable	$184.6M+0.4%	$183.9M-11.1%	$206.9M-12.8%	$237.1M+8.8%	$217.9M-2.6%	$223.7M-7.3%	$241.4M+5.9%	$227.9M
Goodwill	$980.6M+0.2%	$978.9M-0.2%	$980.9M+1.3%	$968.6M+0.4%	$964.6M-1.8%	$982.6M+1.0%	$972.7M+0.2%	$971.0M
Total Liabilities	$511.7M-8.7%	$560.3M-12.3%	$639.1M+2.0%	$626.2M+5.8%	$591.9M-0.9%	$597.4M-5.9%	$635.0M-10.2%	$706.8M
Current Liabilities	$140.4M-2.8%	$144.5M-17.8%	$175.8M+3.9%	$169.2M+4.9%	$161.3M+13.5%	$142.1M-10.8%	$159.4M+6.4%	$149.8M
Long-Term Debt	$260.0M-13.3%	$300.0M-13.3%	$346.0M+4.8%	$330.0M+10.0%	$300.0M0.0%	$300.0M-6.0%	$319.0M-18.0%	$389.0M
Total Equity	$2.0B+2.3%	$2.0B+2.4%	$1.9B-4.9%	$2.0B-2.9%	$2.1B-2.8%	$2.1B+3.4%	$2.1B+2.7%	$2.0B
Retained Earnings	$1.1B+2.2%	$1.1B+1.5%	$1.1B-10.9%	$1.2B-7.0%	$1.3B-4.1%	$1.3B+1.2%	$1.3B+2.1%	$1.3B

TECH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$287.6M-3.8%	$299.0M+17.5%	$254.4M-21.8%	$325.3M-7.6%	$352.2M+71.6%	$205.2M
Capital Expenditures	$31.0M-50.7%	$62.9M+64.4%	$38.2M-14.8%	$44.9M+1.4%	$44.3M-14.4%	$51.7M
Free Cash Flow	$256.6M+8.7%	$236.1M+9.2%	$216.1M-22.9%	$280.4M-8.9%	$307.9M+100.6%	$153.5M
Investing Cash Flow	-$35.2M+82.7%	-$203.0M+23.6%	-$265.6M-174.3%	-$96.9M+60.2%	-$243.5M-998.7%	$27.1M
Financing Cash Flow	-$253.9M-107.4%	-$122.4M-641.2%	$22.6M+109.3%	-$242.9M-288.2%	-$62.6M+66.0%	-$183.8M
Dividends Paid	$50.4M-0.1%	$50.4M+0.3%	$50.3M+0.2%	$50.2M+1.1%	$49.6M+1.5%	$48.9M
Share Buybacks	$275.7M+244.5%	$80.0M+309.2%	$19.6M-87.8%	$160.9M+272.8%	$43.2M-13.8%	$50.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$82.4M+198.8%	$27.6M-71.9%	$98.2M+138.8%	$41.1M-51.2%	$84.3M+32.0%	$63.9M-15.4%	$75.5M-6.8%	$81.0M
Capital Expenditures	$5.9M+10.4%	$5.4M+9.7%	$4.9M-51.7%	$10.1M+48.4%	$6.8M-25.6%	$9.2M-49.0%	$18.0M+9.4%	$16.4M
Free Cash Flow	$76.5M+244.2%	$22.2M-76.2%	$93.3M+201.0%	$31.0M-60.0%	$77.5M+41.7%	$54.7M-4.9%	$57.5M-10.9%	$64.5M
Investing Cash Flow	-$5.9M-1078.7%	$605K+49.0%	$406K+104.6%	-$8.9M-76.3%	-$5.0M+76.8%	-$21.7M-146.2%	-$8.8M+46.4%	-$16.4M
Financing Cash Flow	-$49.0M-10.8%	-$44.2M+51.1%	-$90.5M-32.9%	-$68.0M+18.8%	-$83.8M-624.5%	-$11.6M+80.7%	-$60.1M-14.7%	-$52.4M
Dividends Paid	$12.5M+0.2%	$12.4M+0.5%	$12.4M-1.5%	$12.6M-1.2%	$12.7M+0.4%	$12.7M+0.5%	$12.6M+0.4%	$12.6M
Share Buybacks	$0-100.0%	$24K-100.0%	$100.1M0.0%	$100.0M	N/A	N/A	$0	$0

TECH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	64.8%-1.6pp	66.4%-1.3pp	67.7%-0.7pp	68.4%+0.5pp	68.0%+2.6pp	65.4%
Operating Margin	8.4%-9.4pp	17.8%-8.5pp	26.3%-0.5pp	26.8%+1.3pp	25.5%+4.2pp	21.3%
Net Margin	6.0%-8.5pp	14.5%-10.6pp	25.1%+0.5pp	24.6%+9.5pp	15.1%-16.0pp	31.0%
Return on Equity	3.8%-4.3pp	8.1%-6.4pp	14.5%-1.5pp	16.0%+7.0pp	9.0%-7.6pp	16.6%
Return on Assets	2.9%-3.4pp	6.2%-4.6pp	10.8%-1.0pp	11.9%+5.7pp	6.2%-5.1pp	11.3%
Current Ratio	3.46-0.4	3.87-1.0	4.84+1.4	3.44+0.1	3.35-1.5	4.88
Debt-to-Equity	0.18+0.0	0.15-0.0	0.18+0.0	0.14-0.1	0.21-0.0	0.25
FCF Margin	21.0%+0.7pp	20.4%+1.3pp	19.0%-6.3pp	25.4%-7.7pp	33.1%+12.3pp	20.8%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	64.6%-1.0pp	65.6%+2.9pp	62.7%-5.1pp	67.9%+2.6pp	65.3%+2.0pp	63.2%-3.2pp	66.4%-1.0pp	67.4%
Operating Margin	18.4%+1.8pp	16.6%+24.2pp	-7.5%-19.8pp	12.2%-3.7pp	16.0%+2.1pp	13.8%-1.2pp	15.0%-7.1pp	22.1%
Net Margin	12.8%-0.5pp	13.3%+18.9pp	-5.6%-12.7pp	7.1%-4.6pp	11.8%+0.1pp	11.6%-1.7pp	13.3%-2.9pp	16.2%
Return on Equity	1.9%-0.1pp	1.9%+2.9pp	-0.9%-2.0pp	1.1%-0.6pp	1.7%+0.1pp	1.6%-0.4pp	2.0%-0.5pp	2.4%
Return on Assets	1.5%0.0pp	1.5%+2.2pp	-0.7%-1.5pp	0.9%-0.5pp	1.3%+0.1pp	1.2%-0.3pp	1.5%-0.3pp	1.8%
Current Ratio	4.54+0.3	4.22+0.8	3.46-0.2	3.71-0.2	3.94-0.6	4.56+0.7	3.87-0.2	4.08
Debt-to-Equity	0.13-0.0	0.15-0.0	0.18+0.0	0.16+0.0	0.140.0	0.14-0.0	0.15-0.0	0.19
FCF Margin	25.9%+18.1pp	7.8%-21.7pp	29.4%+19.6pp	9.8%-16.3pp	26.1%+7.2pp	18.9%+0.1pp	18.8%-2.5pp	21.3%

Similar Companies

Jazz Pharmaceuticals Plc JAZZ

$11.5B

Halozyme Thrp HALO

$7.6B

Verona Pharma VRNA

$9.2B

Revolution Medicines, Inc. RVMD

$19.6B

Blueprint Medicines Corp BPMC

$8.4B

Frequently Asked Questions

What is Bio-Techne Corp's annual revenue?

Bio-Techne Corp (TECH) reported $1.2B in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bio-Techne Corp's revenue growing?

Bio-Techne Corp (TECH) revenue grew by 5.2% year-over-year, from $1.2B to $1.2B in fiscal year 2025.

Is Bio-Techne Corp profitable?

Yes, Bio-Techne Corp (TECH) reported a net income of $73.4M in fiscal year 2025, with a net profit margin of 6.0%.

What is Bio-Techne Corp's EBITDA?

Bio-Techne Corp (TECH) had EBITDA of $212.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bio-Techne Corp have?

As of fiscal year 2025, Bio-Techne Corp (TECH) had $162.2M in cash and equivalents against $346.0M in long-term debt.

What is Bio-Techne Corp's gross margin?

Bio-Techne Corp (TECH) had a gross margin of 64.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bio-Techne Corp's operating margin?

Bio-Techne Corp (TECH) had an operating margin of 8.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bio-Techne Corp's net profit margin?

Bio-Techne Corp (TECH) had a net profit margin of 6.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Bio-Techne Corp pay dividends?

Yes, Bio-Techne Corp (TECH) paid $0.32 per share in dividends during fiscal year 2025.

What is Bio-Techne Corp's return on equity (ROE)?

Bio-Techne Corp (TECH) has a return on equity of 3.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bio-Techne Corp's free cash flow?

Bio-Techne Corp (TECH) generated $256.6M in free cash flow during fiscal year 2025. This represents a 8.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bio-Techne Corp's operating cash flow?

Bio-Techne Corp (TECH) generated $287.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bio-Techne Corp's total assets?

Bio-Techne Corp (TECH) had $2.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bio-Techne Corp's capital expenditures?

Bio-Techne Corp (TECH) invested $31.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bio-Techne Corp spend on research and development?

Bio-Techne Corp (TECH) invested $99.5M in research and development during fiscal year 2025.

Does Bio-Techne Corp buy back shares?

Yes, Bio-Techne Corp (TECH) spent $275.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Bio-Techne Corp have outstanding?

Bio-Techne Corp (TECH) had 155M shares outstanding as of fiscal year 2025.

What is Bio-Techne Corp's current ratio?

Bio-Techne Corp (TECH) had a current ratio of 3.46 as of fiscal year 2025, which is generally considered healthy.

What is Bio-Techne Corp's debt-to-equity ratio?

Bio-Techne Corp (TECH) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bio-Techne Corp's return on assets (ROA)?

Bio-Techne Corp (TECH) had a return on assets of 2.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bio-Techne Corp's Altman Z-Score?

Bio-Techne Corp (TECH) has an Altman Z-Score of 9.20, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bio-Techne Corp's Piotroski F-Score?

Bio-Techne Corp (TECH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bio-Techne Corp's earnings high quality?

Bio-Techne Corp (TECH) has an earnings quality ratio of 3.92x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bio-Techne Corp cover its interest payments?

Bio-Techne Corp (TECH) has an interest coverage ratio of 12.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bio-Techne Corp?

Bio-Techne Corp (TECH) scores 58 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.